|
Cost-Effectiveness Analysis of First-Line Nivolumab Plus Cabozantinib for Advanced Renal Cell Carcinoma in the United States |
|
|
|
Titel: |
Cost-Effectiveness Analysis of First-Line Nivolumab Plus Cabozantinib for Advanced Renal Cell Carcinoma in the United States |
Auteur: |
Liao, Weiting Lei, Wanting Feng, Mingyang Yang, Yang Wu, Qiuji Zhou, Kexun Bai, Liangliang Wen, Feng Li, Qiu |
Verschenen in: |
Advances in therapy |
Paginering: |
Jaargang 38 () nr. 12 pagina's 5662-5670 |
Jaar: |
2021-10-18 |
Inhoud: |
|
Uitgever: |
Springer Healthcare, Cheshire |
Bronbestand: |
Elektronische Wetenschappelijke Tijdschriften |
|
|
|
|